Inhibiting angiogenesis by oral immunisation with poly(1-caprolactone)–poly(ethylene glycol)–poly(1-caprolactone) nanoparticle-encapsulated basic fibroblast growth factor

摘要

Attempts to neutralise basic fibroblast growth factor (BFGF) have met some success in blocking neovascularisation. The authors describe annoral protein vaccine based on human BFGF encapsulated poly(1-caprolactone)–poly(ethylene glycol)–poly(1-caprolactone) (PCEC) nanopar-nticles. The human BFGF encapsulated PCEC nanoparticles (BFGF/PCEC) were monodisperse with the mean diameter of 142 nm and cannslow-released BFGF in vitro. After mice were orally immunised with four dosages of BFGF/PCEC nanoparticles, BFGF-specific autoantibodyntiter in sera was 1600. Furthermore, alginate-encapsulated tumour cell assay implied that oral immunisation with BFGF/PCEC efficiently inhib-nited angiogenesis in vivo. Thus, oral immunisation with BFGF/PCEC nanoparticles may be a novel strategy to suppress angiogenesis, and thisnvaccine may have promising application in cancer immunotherapy.